Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.
As a long-time leader in sleep medicine, Jazz has been at the forefront of providing therapies and support for our patients living with serious, debilitating neurologic disorders. More recently we have expanded into additional disease areas with high unmet needs, including rare, severe childhood-onset epilepsies, through our acquisition of GW Pharmaceuticals – which has pioneered cannabinoid science for over two decades to bring regulatory-approved therapeutic options to support patients and their families.
We continue to expand our understanding of the brain, investigating therapies to treat disorders in neurology and neuropsychiatry. Using our world-leading cannabinoid research platform, we plan to explore how this, combined with our other world-class proprietary programmes, can unlock much-needed solutions for even more patients.
Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries.
Be sure to catch the Sponsor-led Satellite Session on 11 October at 16:15 in the main Auditorium.